Miriam Bujny

Miriam is the Chief Development Officer of Sapreme and is an experienced translational science lead with background in RNA and antibody therapeutics. She uses this background at Sapreme to drive the development of next-generation therapeutics that circumvent endosomal entrapment. Over the last 14 years, Miriam has held leadership positions in various drug discovery and clinical development roles at ProQR, Johnson & Johnson and Crucell across a variety of rare  and infectious disease programs. Miriam holds a Ph.D. in Biochemistry from the University of Bristol with a specialization in endosomal biology. She completed postdoctoral training with Professor Xiaowei Zhuang at the department of Chemistry and Chemical Biology at Harvard University.